Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03193918 · ClinicalTrials.gov registry record · Phase 1
Study of Crenolanib With Ramucirumab and Paclitaxel for Advanced Esophagogastric Adenocarcinoma
A Phase 1 study, sponsored by Arog Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT03193918 is a Phase 1 study that has completed, run by Arog Pharmaceuticals. The registered enrollment target is 30 participants.
The verdict
NCT03193918, a Phase 1 study, has completed, sponsored by Arog Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
This is a single-arm phase I/Ib study of crenolanib combined with ramucirumab/paclitaxel as second line therapy for patients with advanced/metastatic adenocarcinoma of the esophagus, GEJ or stomach. Patients will be enrolled in two phases; dose escalation phase and dose expansion phase.
Interventions
- DRUG Paclitaxel
- DRUG Ramucirumab
- DRUG Crenolanib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2017-04-14 |
| Est. Completion | 2020-07-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03193918
The ClinicalTrials.gov registry entry for NCT03193918 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Arog Pharmaceuticals, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Paclitaxel is the first listed.
NCT03193918 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03193918 about?
NCT03193918 is a clinical study titled "Study of Crenolanib With Ramucirumab and Paclitaxel for Advanced Esophagogastric Adenocarcinoma". This is a single-arm phase I/Ib study of crenolanib combined with ramucirumab/paclitaxel as second line therapy for patients with advanced/metastatic adenocarcinoma of the esophagus, GEJ or stomach. Patients will be enrolled in two phases; dose escalation phase and dose expansion phase.
What is the current status of trial NCT03193918?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2017-04-14. Estimated completion is 2020-07-15.
What interventions are being tested in trial NCT03193918?
The interventions under investigation include: Paclitaxel (DRUG), Ramucirumab (DRUG), Crenolanib (DRUG).
Who is sponsoring clinical trial NCT03193918?
This trial is sponsored by Arog Pharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.